British Columbia Adds Insulins To Its Biosimilar Switching Policy

Canadian Province Says Patients Have Six Months To Make The Transition

British Columbia and Canada flags
British Columbia’s biosimilar switching policy now includes Humalog and NovoRapid • Source: Alamy

More from Biosimilars

More from Products